Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 70

1.

Controversial association between leptomeningeal enhancement and demyelinated cortical lesions in multiple sclerosis.

Absinta M, Ontaneda D.

Mult Scler. 2020 Feb;26(2):135-136. doi: 10.1177/1352458519892186. No abstract available.

PMID:
32052711
2.

Palatal myoclonus, abnormal eye movements, and olivary hypertrophy in GAD65-related disorder.

Macaron G, Willis MA, Ontaneda D, Fernandez H, Kim S, Jones SE, Pioro EP, Cohen JA.

Neurology. 2020 Feb 11;94(6):273-275. doi: 10.1212/WNL.0000000000008926. Epub 2019 Dec 31. No abstract available.

PMID:
31892635
3.

Pregnancy and multiple sclerosis: Risk of unplanned pregnancy and drug exposure in utero.

Smith AL, Cohen JA, Ontaneda D, Rensel M.

Mult Scler J Exp Transl Clin. 2019 Dec 12;5(4):2055217319891744. doi: 10.1177/2055217319891744. eCollection 2019 Oct-Dec.

4.

Technology-enabled comprehensive characterization of multiple sclerosis in clinical practice.

Baldassari LE, Nakamura K, Moss BP, Macaron G, Li H, Weber M, Jones SE, Rao SM, Miller D, Conway DS, Bermel RA, Cohen JA, Ontaneda D, McGinley MP.

Mult Scler Relat Disord. 2019 Nov 14;38:101525. doi: 10.1016/j.msard.2019.101525. [Epub ahead of print]

PMID:
31759186
5.

Serum neurofilament light chain concentration in a phase 1/2 trial of autologous mesenchymal stem cell transplantation.

Baldassari LE, Planchon SM, Bermel RA, Nakamura K, Fisher E, Feng J, Sakaie KE, Ontaneda D, Cohen JA.

Mult Scler J Exp Transl Clin. 2019 Nov 5;5(4):2055217319887198. doi: 10.1177/2055217319887198. eCollection 2019 Oct-Dec.

6.

Pragmatic clinical trials for treating relapsing multiple sclerosis.

Mowry EM, Ontaneda D, Evangelou N, Newsome SD.

Lancet Neurol. 2019 Dec;18(12):1075. doi: 10.1016/S1474-4422(19)30386-2. No abstract available.

PMID:
31701890
7.

Prevalence of multiple sclerosis in Cuenca, Ecuador.

Correa-Díaz EP, Ortiz MA, Toral AM, Guillen F, Terán E, Ontaneda D, García-Castillo M, Jácome-Sánchez C, Torres-Herrán G, Ortega-Heredia A, Buestán ME, Murillo-Calle J, Raza P, Baño G.

Mult Scler J Exp Transl Clin. 2019 Oct 30;5(4):2055217319884952. doi: 10.1177/2055217319884952. eCollection 2019 Oct-Dec.

8.

Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up.

Vollmer B, Ontaneda D, Harris H, Nair K, Bermel RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM.

J Neurol Sci. 2019 Dec 15;407:116498. doi: 10.1016/j.jns.2019.116498. Epub 2019 Oct 15.

9.

Tuberculosis screening in multiple sclerosis: effect of disease-modifying therapies and lymphopenia on the prevalence of indeterminate TB screening results in the clinical setting.

Baldassari LE, Feng J, Macaron G, Planchon SM, Alshehri E, Moss BP, Ontaneda D, Willis MA.

Mult Scler J Exp Transl Clin. 2019 Sep 11;5(3):2055217319875467. doi: 10.1177/2055217319875467. eCollection 2019 Jul-Sep.

10.

Vitamin D and MRI measures in progressive multiple sclerosis.

Abbatemarco JR, Fox RJ, Li H, Ontaneda D.

Mult Scler Relat Disord. 2019 Oct;35:276-282. doi: 10.1016/j.msard.2019.08.014. Epub 2019 Aug 13.

PMID:
31445221
11.

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis.

Dutta R, Mahajan KR, Nakamura K, Ontaneda D, Chen J, Volsko C, Dudman J, Christie E, Dunham J, Fox RJ, Trapp BD.

J Vis Exp. 2019 Jul 19;(149). doi: 10.3791/59511.

PMID:
31380830
12.

Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis.

Ontaneda D, Tallantyre E, Kalincik T, Planchon SM, Evangelou N.

Lancet Neurol. 2019 Oct;18(10):973-980. doi: 10.1016/S1474-4422(19)30151-6. Epub 2019 Jul 30. Review.

PMID:
31375366
13.

Diagnosis and Management of Progressive Multiple Sclerosis.

Macaron G, Ontaneda D.

Biomedicines. 2019 Jul 29;7(3). pii: E56. doi: 10.3390/biomedicines7030056. Review.

14.

Neuroemergencies in South America: How to Fill in the Gaps?

Silva GS, Maldonado NJ, Mejia-Mantilla JH, Ortega-Gutierrez S, Claassen J, Varelas P, Suarez JI; Galapagos Neurocritical Care Summit Investigators.

Neurocrit Care. 2019 Dec;31(3):573-582. doi: 10.1007/s12028-019-00775-8.

PMID:
31342447
15.

Exploratory MRI measures after intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.

Feng J, Offerman E, Lin J, Fisher E, Planchon SM, Sakaie K, Lowe M, Nakamura K, Cohen JA, Ontaneda D.

Mult Scler J Exp Transl Clin. 2019 Jun 14;5(2):2055217319856035. doi: 10.1177/2055217319856035. eCollection 2019 Apr-Jun.

16.

Progressive Multiple Sclerosis.

Ontaneda D.

Continuum (Minneap Minn). 2019 Jun;25(3):736-752. doi: 10.1212/CON.0000000000000727. Review.

PMID:
31162314
17.

MOG-related disorders: A new cause of imaging-negative myelitis?

Macaron G, Ontaneda D.

Mult Scler. 2019 Apr 1:1352458519840746. doi: 10.1177/1352458519840746. [Epub ahead of print]

PMID:
30931813
18.

Imaging outcome measures of neuroprotection and repair in MS: A consensus statement from NAIMS.

Oh J, Ontaneda D, Azevedo C, Klawiter EC, Absinta M, Arnold DL, Bakshi R, Calabresi PA, Crainiceanu C, Dewey B, Freeman L, Gauthier S, Henry R, Inglese M, Kolind S, Li DKB, Mainero C, Menon RS, Nair G, Narayanan S, Nelson F, Pelletier D, Rauscher A, Rooney W, Sati P, Schwartz D, Shinohara RT, Tagge I, Traboulsee A, Wang Y, Yoo Y, Yousry T, Zhang Y, Sicotte NL, Reich DS; North American Imaging in Multiple Sclerosis Cooperative.

Neurology. 2019 Mar 12;92(11):519-533. doi: 10.1212/WNL.0000000000007099. Epub 2019 Feb 20. Review. Erratum in: Neurology. 2019 Jul 2;93(1):46.

PMID:
30787160
19.

MS progression is predominantly driven by age-related mechanisms - NO.

McGinley M, Ontaneda D.

Mult Scler. 2019 Jun;25(7):904-906. doi: 10.1177/1352458518819712. Epub 2019 Feb 12. No abstract available.

PMID:
30747571
20.

Multiple sclerosis risk factors contribute to onset heterogeneity.

Briggs FBS, Yu JC, Davis MF, Jiangyang J, Fu S, Parrotta E, Gunzler DD, Ontaneda D.

Mult Scler Relat Disord. 2019 Feb;28:11-16. doi: 10.1016/j.msard.2018.12.007. Epub 2018 Dec 4.

PMID:
30529925

Supplemental Content

Loading ...
Support Center